Doç. Dr. Salih Özgüven
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Neuroendocrine Tumors 9 publicationsSource: OpenAlex / PubMed MeSHView publications
- Liver Neoplasms 8 publications
- Kidney Neoplasms 6 publications
- Carcinoma, Renal Cell 5 publications
- Breast Neoplasms 5 publications
- Lung Neoplasms 4 publications
- Bone Neoplasms 4 publications
- Carcinoma, Hepatocellular 4 publications
- Prostatic Neoplasms 3 publications
- Stomach Neoplasms 2 publications
- Thrombosis 2 publications
- Takayasu Arteritis 2 publications
- Esophageal Neoplasms 2 publications
- Meningeal Neoplasms 2 publications
- Meningioma 2 publications
- Hemangioma 2 publications
- Thyroid Neoplasms 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyNuclear Medicinesaglik.gov.trFrom source
- InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
- Area of workNeuroendocrine TumorsExtracted from 9 publications · Model version —From source
- Publications157 publicationsORCID, OpenAlex, Europe PMCFrom source
- ORCID0000-0002-2790-7206ORCIDFrom source
- Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1392922/doktorlarimiz.html#salih-ozguvensaglik.gov.tr
Scientific work
Publications on Neuroendocrine Tumors
-
Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15020798 PMID 41598735 Open-access full textSource: ORCID
-
Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab
Medicina, 2026
DOI 10.3390/medicina62010098 PMID 41597384 1 citation (Europe PMC) Open-access full textSource: ORCID
-
Vascular FDG Uptake on PET/CT in Patients Receiving Immune Checkpoint Inhibitors
Journal of Oncological Sciences, 2026
DOI 10.37047/jos.galenos.2026.2025-8-9 Open-access full textSource: OpenAlex
-
Interobserver variability in dominant intraprostatic lesion delineation using ⁶⁸Ga-PSMA PET/CT for localized prostate cancer
Reports of Practical Oncology & Radiotherapy, 2026
DOI 10.5603/rpor.110469 PMID 42131465 Open-access full textSource: OpenAlex
-
The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy
Medicina, 2025
DOI 10.3390/medicina61081449 PMID 40870493 1 citation (Europe PMC) Open-access full textSource: ORCID
-
Involvement of Iliofemoral Arteries in PET/CT Is Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Journal of Clinical Medicine, 2025
DOI 10.3390/jcm14238607 PMID 41375908 4 citations (OpenAlex) Open-access full textSource: OpenAlex
-
Physiological bio-distribution of 68Ga-DOTA-TATE in pediatric patients
Annals of Nuclear Medicine, 2025
DOI 10.1007/s12149-025-02040-9 PMID 40106206 3 citations (OpenAlex) Open-access full textSource: OpenAlex
-
Interobserver and intraobserver agreement for equivocal lesions in Ga-68 PSMA PET/CT according to PSMA-RADS 2.0 criteria
Annals of Nuclear Medicine, 2025
DOI 10.1007/s12149-025-02103-x PMID 40928727 Source: OpenAlex
-
Physiological Distribution of <sup>18</sup>F-FDG in the Spinal Cord of Disease-Free Subjects
Molecular imaging and radionuclide therapy, 2025
DOI 10.4274/mirt.galenos.2025.56514 PMID 40370310 2 citations (Europe PMC) Open-access full textSource: Europe PMC
-
Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Indian journal of cancer, 2024
DOI 10.4103/ijc.ijc_649_21 PMID 39960709 Open-access full textSource: Europe PMC